

PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	12/14/2001
First Named Inventor	Pittner, Richard
Art Unit	1646
Examiner Name	LI, RUIXIANG
Attorney Docket Number	0401-UTL-0

Sheet 1 of 8

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Ando, R. et al., Eur J Pharmacol. 2001 Sep 7; 427(1):53-59.	
		Andres et al., Bioorganic & Medicinal Chemistry Letters 13(2003) 2883-2885.	
		Bader, R. et al., Biochemistry. 2002; 41(25):8031-8042.	
		Balasubramaniam, A. et al., Int J Pept Protein Res. 1987 Jan; 29(1):78-83.	
		Balasubramaniam, A. et al., Pept Res. 1988 Sep-1988 Oct 31; 1(1):32-35.	
		Balasubramaniam, A. et al., Peptides 14: 1011-1016 (1993).	
		Balasubramaniam, A., Peptides. 1997; 18(3):445-457.	
		Balasubramaniam et al., Peptides 23 (2002) 1485-1490.	
Y		Beck et al., FEBS 06785 244(1) 119-122 (1989).	
RLi		Beck-Sickinger et al., J Recept Res 1993; 13(1-4) 215-228.	

Examiner Signature	Ruixiang Li	Date Considered	11/17/2005
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

8

Application Number

10/016,969

Filing Date

12/14/2001

First Named Inventor

Pittner, Richard

Art Unit

1646

Examiner Name

LI, RUIXIANG

Attorney Docket Number

0401-UTL-0

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Berglund, M. et al., Exp Biol Med (Maywood). 2003 Mar; 228(3):217-244.	
		Bischoff, A., et al., Trends Pharmacol Sci. 1999 Mar; 20(3):104-106.	
		Boublik, J. H., et al., J Med Chem. 1989 Mar; 32(3):597-601.	
		Cabrele et al., Peptides 22(2001) 365-378.	
		Cabrele, C. et al., J Pept Sci. 2000 Mar; 6(3):97-122.	
		Cabrele, C. et al., J Biol Chem. 2000; 275(46): 36043-36048.	
		Cabrele, C. et al., Biochemistry. 2002 Jun 25; 41(25):8043-8049.	
		Chen, Z. et al., FEBS Lett. 2001 Mar 9; 492(1-2):119-122.	
		Conlon, J. M., Peptides. 2002; 23(2):269-278.	
RLi		Corp, E. S. et al., Peptides. 2001 Mar; 22(3):493-499.	

Examiner
Signature

RuiXiang Li

Date


Considered

11/17/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	12/14/2001
First Named Inventor	Pittner, Richard
Art Unit	1646
Examiner Name	LI, RUIXIANG
Attorney Docket Number	0401-UTL-0

Sheet 3 of 8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Cox, H. M. et al., Regul Pept. 1998; 75-76:3-8.	
		Dumont et al., EP J of Pharmacology, 238 (1993) 37-45.	
		Eto, B. et al., Peptides. 1995; 16(8):1403-1409.	
		Fackelmann USA Today, Health and Science Gut hormone could curb urge to overeat. (Aug 7 2002).	
		Feinstein et al., J. Med. Chem. 1992, 35, 2836-2843.	
		Fournier et al., Molecular Pharmacology, (1994) 45:93-101.	
		Gobbi et al., J. of Neurochemistry (1999) 72m 1663-1670.	
		Gordon et al., Neuroscience Letters, 119 (1990) 187-190.	
		Grundemar et al. Regulatory Peptides 62 (1996) 131-136.	
RLi		Halatchev et al., Endocrinology 145(6) (2004) 2585-2590.	

Examiner
Signature

RuiXiang Li


Date
Considered

11/18/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

8

Attorney Docket Number

0401-UTL-0

Application Number

10/016,969

Filing Date

12/14/2001

First Named Inventor

Pittner, Richard

Art Unit

1646

Examiner Name

LI, RUIXIANG

NON PATENT LITERATURE DOCUMENTSExaminer
Initials*Cite
No.¹

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T²

RLi

Henry et al., Obesity Research (Jan 2005) 13(1): 36-47.

Hu et al., The J. of Biological Chemistry (Oct 1996) 271(42):
26315-26319.

Inui, A., Trends Pharmacol Sci. 1999 Feb; 20(2):43-46.

Kanatani, A. et al., Biochem Biophys Res Commun. 2000 May 27;
272(1):169-173.Kanatani, A. et al., Biochem Biophys Res Commun. 1999 Dec 9;
266(1):88-91.

Keire, D. A. et al., Peptides. 2002; 23(2):305-321.

Keire, D. A. et al., Biochemistry. 2000 Aug 15; 39(32):9935-9942.

Keire, D. A. et al., Am J Physiol. 2000 Jul; 279(1):G126-G131.

Kirby et al., J. Med. Chem. 1993; 36: 3802-3808.

RLi

Kirby et al., J. Med. Chem. 1995; 38: 4579-4586.

Examiner
Signature

RuiXiang Li


Date
Considered

11/17/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	12/14/2001
First Named Inventor	Pittner, Richard
Art Unit	1646
Examiner Name	LI, RUIXIANG
Attorney Docket Number	0401-UTL-0

Sheet 5 of 8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Krstenansky et al., Proc. Natl. Acad. Sci. USA June 1989; 86: 4377-4381.	
		Krstenansky et al., Neuropeptides (1990) 17, 117-120.	
		Leban et al., J. Med. Chem. 1995, 38, 1150-1157.	
		Liu, C. D. et al., J Gastrointest Surg. 2001 Mar-2001 Apr 30; 5(2):147-152.	
		Lundell et al., JBC 270(49) 29123-29128 (1995).	
		Makimura, H. et al., Obesity Poster Abstract No. 118 "Adrenalectomy stimulated hypothalamic proopiomelanocortin mRNA but does not correct obesity in diet-induce obese mice."	
		Markison S., et al., Obesity Poster Abstract No. 119 "Selective melanin-concentrating hormone receptor antagonists decrease feeding in rodents."	
		Martin, N. M. et al., Int J Obes Relat Metab Disord. 2004 Jul; 28(7):886-893.	
		Mashiko et al., Endocrinology (2003) 144(5): 1793-1801 .	
RLi		Mashiko et al., Obesity Poster Abstract No. 120 "Characterization of neuropeptide Y Y5 receptor mediated obesity in mice."	

Examiner
Signature

RuiXiang Li


Date
Considered

11/17/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	12/14/2001
First Named Inventor	Pittner, Richard
Art Unit	1646
Examiner Name	LI, RUIXIANG
Attorney Docket Number	0401-UTL-0

Sheet 6 of 8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Mullins, D. et al., Mol Pharmacol. 2001; 60(3):534-540.	
		Murakami, Y. et al., J Med Chem. 1999 Jul 15; 42(14):2621-2632.	
		Murase et al., J Biochem (Tokyo) 1996 Jan 119(1): 37-41.	
		Parker, E. M. et al., Eur J Pharmacol. 1998 May 15; 349(1):97-105.	
		Parker, E. M. et al., Peptides. 2000 Mar; 21(3):393-399.	
		Parker et al., Can. J. Physiol. Pharmacol. (2000); 78: 150-161.	
		Potter et al., EP J. of Pharmacology 267 (1994) 253-262.	
		Renshaw, D. et al., Curr Drug Targets (2005) Mar; 6(2):171-179.	
✓		Rico, L. et al., Obesity Poster Abstract No. 117 "Early and dissociated leptin and insulin resistance in transgenic mice overexpressing leptin from keratinocytes."	
RLi		Rist et al., FEBS Letters 394 (1996) 169-173.	

Examiner
Signature

RuiXiang Li


Date
Considered

11/17/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	12/14/2001
First Named Inventor	Pittner, Richard
Art Unit	1646
Examiner Name	LI, RUIXIANG
Attorney Docket Number	0401-UTL-0

Sheet 7

of

8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Rist et al., Eur. J. Biochem. (1997); 247: 1019-1028 .	
		Sato, N. et al., J Med Chem. 2003 Feb 27; 46(5):666-669.	
		Shan et al., Science (27Sep 2002); 297: 2275-2279.	
		Sheikh, S. P. Am J Physiol. 1991 Nov; 261(5 Pt 1):G701-G715.	
		Silva, A. P. et al., Clin Chim Acta. 2002 Dec; 326(1-2):3-25.	
		Small, C. J., et al., Proc Natl Acad Sci U S A. 1997 Oct 14; 94(21):11686-11691.	
		Soll et al. Eur. J. Biochem (2001); 268: 2828-2837 .	
		Tatemoto, K. et al., Proc Natl Acad Sci U S A. 1992 Feb 15; 89(4):1174-1178.	
ix		Thum, A. et al.; Exp Clin Endocrinol Diabetes. 2002; 110(3):113-118.	
RLi		Totheroh, G., "Science Offers Promising Treatment for an Overweight Nation" CBN News (Sept 4, 2003).	

Examiner
Signature

RuiXiang L.


Date
Considered

11/17/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1001

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	12/14/2001
First Named Inventor	Pittner, Richard
Art Unit	1646
Examiner Name	LI, RUIXIANG
Attorney Docket Number	0401-UTL-0

Sheet 8 of 8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RL		Tschop, M. et al., Nature. 2004 Jul 8; 430(6996):1 p following 165; discussion 2 p following 165.	
		Tseng, W. W. et al., Peptides. 2002; 23(2):389-395.	
		Turnbull, A. V. et al., Diabetes. 2002; 51(8):2441-2449.	
		Walker, M. W. et al., Peptides. 1997;18(4):609-612.	
		Walker et al. The J of Neuroscience Jul 1988, 8 (7): 2438-2446.	
		Weinberg, D. H. et al., J Biol Chem. 1996 Jul 12; 271(28):16435-16438.	
		Wilding, J. P., Diabet Med. 2002 Aug; 19(8):619-627.	
		HYPERDICTIONARY - definition of "Structure Activity Relationship".	
RL			

Examiner Signature	RuiXiang Li	Date Considered	11/17/2005
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.